Efficacy & Safety of Resatorvid in Adults With Severe Sepsis

Summary

The purpose of this study is to determine the optimal dose of Resatorvid for reducing 28-day all-cause mortality in subjects with severe sepsis.

Timeline

Start

2005-09

Primary completion

2007-02

Completion

2007-02

Outcome

Missed primary endpoint

paper 17% in the high-dose group (p = .26 for placebo vs. high dose). PMID 20562702 ↗

Publications

• Results Rice TW, Wheeler AP, Bernard GR, Vincent JL, Angus DC, Aikawa N, Demeyer I, Sainati S, Amlot N, Cao C, Ii M, Matsuda H, Mouri K, Cohen J. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med. 2010 Aug;38(8):1685-94. doi: 10.1097/CCM.0b013e3181e7c5c9.

Drugs

Indications